Sign in

You're signed outSign in or to get full access.

Intellia Therapeutics (NTLA)

--

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Intellia Therapeutics.

Q3 2025

→

Q4 2024

→

Q3 2024

→

Q2 2024

→

Executives

Executive leadership at Intellia Therapeutics.

John Leonard

John Leonard

Detailed

President and Chief Executive Officer

CEO
BS

Birgit Schultes

Detailed

Executive Vice President, Chief Scientific Officer

DL

David Lebwohl

Detailed

Executive Vice President, Chief Medical Officer

ED

Edward Dulac

Detailed

Executive Vice President, Chief Financial Officer and Treasurer

EC

Eliana Clark

Detailed

Executive Vice President, Chief Technology Officer

JB

James Basta

Detailed

Executive Vice President, General Counsel and Corporate Secretary

Board Members

Board of directors at Intellia Therapeutics.

BG

Brian Goff

Detailed

Director

FV

Frank Verwiel

Detailed

Chairperson of the Board

FC

Fred Cohen

Detailed

Director

GK

Georgia Keresty

Detailed

Director

JG

Jesse Goodman

Detailed

Director

MB

Muna Bhanji

Detailed

Director

WC

William Chase

Detailed

Director

Analyst Coverage

Research analysts who have asked questions during Intellia Therapeutics earnings calls.

YZ

Yanan Zhu

Wells Fargo Securities

6 questions for NTLA

Also covers: ADAP, AFMD, ARCT +13 more
BC

Brian Cheng

JPMorgan Chase & Co.

5 questions for NTLA

Also covers: ALLO, BEAM, CHRS +11 more
Alec Stranahan

Alec Stranahan

Bank of America

4 questions for NTLA

Also covers: AGIO, ALEC, BEAM +12 more
Joseph Thome

Joseph Thome

TD Cowen

4 questions for NTLA

Also covers: ALKS, AMLX, ARDX +12 more
LI

Luca Issi

RBC Capital Markets

4 questions for NTLA

Also covers: ADVM, ALLO, ALNY +13 more
ST

Silvan Tuerkcan

Citizens JMP

4 questions for NTLA

Also covers: CLLS, EXEL, MGNX +2 more
DL

David Lebowitz

Citigroup Inc.

3 questions for NTLA

Also covers: ALNY, ARWR, ASND +11 more
Jay Olson

Jay Olson

Oppenheimer & Co. Inc.

3 questions for NTLA

Also covers: ACAD, AMGN, BIIB +23 more
Jonathan Miller

Jonathan Miller

Evercore ISI

3 questions for NTLA

Also covers: APLS, ARVN, ATRA +9 more
MR

Maurice Raycroft

Jefferies Financial Group

3 questions for NTLA

Also covers: ABEO, AFMD, ALNY +14 more
Rick Bienkowski

Rick Bienkowski

Cantor Fitzgerald

3 questions for NTLA

Also covers: BEAM, LEGN
WP

William Pickering

Sanford C. Bernstein & Co.

3 questions for NTLA

Also covers: ALLO, ARWR, BEAM +3 more
Andy Chen

Andy Chen

Wolfe Research, LLC

2 questions for NTLA

Also covers: ARGX, CRNX, IMVT +7 more
E

Emma

Piper Sandler

2 questions for NTLA

Also covers: MDGL
HW

Huidong Wang

Barclays

2 questions for NTLA

Also covers: ALNY, BCRX, BEAM +15 more
Jack Allen

Jack Allen

Robert W. Baird & Co.

2 questions for NTLA

Also covers: ACAD, ALLO, BLUE +8 more
J

Jake

Craig-Hallum Capital Group

2 questions for NTLA

Also covers: BFLY
KB

Konstantinos Biliouris

BMO Capital Markets

2 questions for NTLA

Also covers: ALNY, BEAM, BMRN +3 more
LR

Lidiya Rizova

Leerink Partners

2 questions for NTLA

MF

Mani Foroohar

Leerink Partners

2 questions for NTLA

Also covers: ADVM, ALNY, ARWR +9 more
M

Mark

Stifel

2 questions for NTLA

Also covers: MIRM, SLNO
MR

Maury Raycroft

Jefferies

2 questions for NTLA

Also covers: ABEO, ALNY, ARWR +14 more
M

Mike

Northland Securities

2 questions for NTLA

Also covers: MITK
Mitchell Kapoor

Mitchell Kapoor

H.C. Wainwright & Co.

2 questions for NTLA

Also covers: CTMX, HALO, INM +7 more
MM

Myles Minter

William Blair & Company

2 questions for NTLA

Also covers: ALEC, ALNY, ARCT +12 more
Salveen Richter

Salveen Richter

Goldman Sachs

2 questions for NTLA

Also covers: ACAD, AGIO, ALLO +21 more
Shelby

Shelby

RBC Capital Markets

2 questions for NTLA

Also covers: AGIO, FULC, RARE
TL

Troy Langford

TD Cowen

2 questions for NTLA

Also covers: ALKS, AXSM, JAZZ
A

Aaron

Bank of America Corporation

1 question for NTLA

Also covers: GH, LH
Brandon Frith

Brandon Frith

Wolfe Research, LLC

1 question for NTLA

Also covers: INCY, INSM, ROIV
Cheng Li

Cheng Li

Oppenheimer & Co. Inc.

1 question for NTLA

Also covers: EDIT, EXEL, INO +3 more
DG

Dae Gon Ha

Stifel

1 question for NTLA

Also covers: ABEO, BEAM, CRBP +10 more
Farzin Haque

Farzin Haque

Jefferies

1 question for NTLA

Also covers: ABEO, ARWR, AUPH +3 more
Gena Wang

Gena Wang

Barclays

1 question for NTLA

Also covers: ALNY, BCRX, BLUE +13 more
Hang Hu

Hang Hu

Barclays

1 question for NTLA

Also covers: VIR
HT

Hannah Tran

Wolfe Research

1 question for NTLA

JL

Joon Lee

Truist Securities

1 question for NTLA

Also covers: ADVM, ALKS, AXSM +15 more
Kostas Biliouris

Kostas Biliouris

BMO Capital Markets

1 question for NTLA

Also covers: ALNY, BMRN, LEGN +2 more
Liisa Bayko

Liisa Bayko

Evercore ISI

1 question for NTLA

Also covers: ALT, BCRX, INSM +7 more
LN

Lili Nsongo

iA Capital Markets

1 question for NTLA

Also covers: ARCT, VYGR
LM

Lut Ming Cheng

JPMorgan Chase & Co.

1 question for NTLA

Also covers: ALLO, CHRS, EDIT +3 more
Mark Aleynick

Mark Aleynick

Goldman Sachs

1 question for NTLA

Also covers: ALLO, FOLD
Matthew Guggenbiller

Matthew Guggenbiller

Bank of America

1 question for NTLA

Also covers: AGIO, MRNA
MH

Matthew Harrison

Bank of America

1 question for NTLA

Also covers: AXSM, RVMD
Mehdi Goudarzi

Mehdi Goudarzi

Truist Securities

1 question for NTLA

Also covers: ARGX, EDIT, RARE +1 more
Ry Forseth

Ry Forseth

Guggenheim Securities

1 question for NTLA

Also covers: KRYS, SLNO, SRPT +1 more
Terence Flynn

Terence Flynn

Morgan Stanley

1 question for NTLA

Also covers: ABBV, AMGN, ARVN +17 more
WI

Whitney Ijem

Canaccord Genuity Inc.

1 question for NTLA

Also covers: ARCT, BOLD, GUTS +5 more
WS

William Sanger

Leerink Partners

1 question for NTLA

Yuriy Slutskyy

Yuriy Slutskyy

BMO Capital Markets

1 question for NTLA

Latest news

Recent press releases and 8-K filings for NTLA.

Intellia Therapeutics Reports Q4 2025 Financial Results and Provides Clinical Updates
NTLA
Earnings
Product Launch
Guidance Update
  • Intellia Therapeutics reported $605.1 million in cash, cash equivalents, and marketable securities as of December 31, 2025, with a cash runway expected into the second half of 2027.
  • For the fourth quarter of 2025, collaboration revenue increased to $23 million from $12.9 million in the prior year quarter, while net loss significantly decreased to $95.8 million from $128.9 million.
  • The company anticipates top-line data for its lonvo-z Phase 3 HAELO trial for hereditary angioedema (HAE) by mid-2026, with a Biologics License Application (BLA) submission planned for the second half of 2026 and a potential launch in the first half of 2027.
  • Enrollment for the Nex-z Phase 3 trials (MAGNITUDE and MAGNITUDE-2) for ATTR amyloidosis was suspended and subsequently placed on clinical hold by the FDA in October 2025 due to elevated liver transaminases and total bilirubin in a patient; the company expects to restart enrollment in MAGNITUDE and complete enrollment in MAGNITUDE-2 in 2026.
1 day ago
Transcript
Intellia Therapeutics Reports Q4 2025 Results and Provides Clinical Program Updates
NTLA
Earnings
Product Launch
Guidance Update
  • Intellia Therapeutics reported a net loss of $95.8 million for Q4 2025, an improvement from $128.9 million in the prior-year quarter, with collaboration revenue increasing to $23 million for Q4 2025.
  • As of December 31, 2025, the company held $605.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2027.
  • Enrollment for the lonvo-z HAELO Phase 3 clinical trial for hereditary angioedema (HAE) was completed in September 2025, with top-line data anticipated by mid-2026 and a Biologics License Application (BLA) submission planned for the second half of 2026.
  • The FDA lifted the clinical hold on the MAGNITUDE-2 trial for nex-z (ATTR amyloidosis with polyneuropathy) in late January 2026, with enrollment expected to be completed in the second half of 2026, while discussions with the FDA regarding the MAGNITUDE trial (cardiomyopathy) are ongoing.
1 day ago
Transcript
Intellia Therapeutics Reports Q4 2025 Financials and Clinical Trial Progress for nex-z and lonvo-z
NTLA
Earnings
Guidance Update
Product Launch
  • Intellia Therapeutics reported a cash, cash equivalents, and marketable securities balance of $605.1 million as of December 31, 2025, and expects this to be sufficient to fund operations into the second half of 2027.
  • The FDA lifted the clinical hold on the MAGNITUDE-2 trial for nex-z in ATTR amyloidosis (polyneuropathy) in late January 2026, with enrollment expected to complete in the second half of 2026; however, the hold on the larger MAGNITUDE trial (cardiomyopathy) remains ongoing.
  • The HAELO phase 3 clinical trial for lonvo-z in hereditary angioedema (HAE) completed enrollment with 80 patients in September 2025, ahead of schedule, with top-line data expected by mid-2026 and a potential launch in 2027.
  • For the fourth quarter of 2025, collaboration revenue increased to $23 million from $12.9 million in the prior-year quarter, and the net loss significantly decreased to $95.8 million from $128.9 million in Q4 2024.
1 day ago
Transcript
Intellia Therapeutics Announces Q4 and Full-Year 2025 Results and Key Program Updates
NTLA
Earnings
Guidance Update
New Projects/Investments
  • Intellia Therapeutics reported its fourth quarter and full-year 2025 financial results, showing an increased collaboration revenue and a reduced net loss compared to the prior year.
  • The company ended 2025 with $605.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2027.
  • For its lonvo-z program for HAE, Intellia expects to report topline Phase 3 clinical data by mid-2026, with a Biologics License Application (BLA) submission planned for the second half of 2026 and an anticipated U.S. launch in the first half of 2027.
  • Regarding its nex-z program, the FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial for ATTRv-PN, with enrollment completion expected in the second half of 2026. Engagement with the FDA is ongoing for the clinical hold on the MAGNITUDE Phase 3 trial for ATTR-CM.
MetricQ4 2024FY 2024Q4 2025FY 2025
Collaboration Revenue ($USD Thousands)12,874 57,877 23,017 67,671
R&D Expenses ($USD Thousands)116,877 466,311 88,652 388,861
G&A Expenses ($USD Thousands)32,444 125,829 33,075 119,800
Net Loss ($USD Thousands)(128,898) (519,021) (95,786) (412,694)
Cash, cash equivalents and marketable securities (as of period end) ($USD Thousands)861,730 861,730 605,134 605,134
1 day ago
8-K
Intellia Therapeutics Announces Q4 and Full-Year 2025 Financial Results and Business Updates
NTLA
Earnings
Guidance Update
New Projects/Investments
  • Intellia Therapeutics ended 2025 with approximately $605.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2027.
  • For the fourth quarter of 2025, the company reported collaboration revenue of $23.0 million and a net loss of $95.8 million.
  • HAELO Phase 3 clinical data for lonvo-z in HAE is expected by mid-2026, with a Biologics License Application (BLA) submission planned for the second half of 2026 and an anticipated U.S. launch in the first half of 2027.
  • The FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial for nex-z in ATTRv-PN on January 27, 2026, with enrollment completion expected in the second half of 2026; however, engagement with the FDA is ongoing to resolve the clinical hold on the MAGNITUDE Phase 3 trial for ATTR-CM.
1 day ago
Press Release
Intellia Therapeutics Announces FDA Lifts Clinical Hold on MAGNITUDE-2 Trial
NTLA
New Projects/Investments
  • The FDA has removed the clinical hold on Intellia Therapeutics' Investigational New Drug application (IND) for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
  • Intellia plans to resume patient enrollment and dosing for the MAGNITUDE-2 trial, having aligned with the FDA on study modifications and enhanced safety monitoring of liver laboratory tests.
  • The clinical holds on both MAGNITUDE and MAGNITUDE-2 were initially imposed on October 29, 2025, following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient dosed with nex-z in the MAGNITUDE trial.
  • Engagement with the FDA is ongoing regarding the clinical hold on the MAGNITUDE Phase 3 clinical trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), with an update expected once alignment is achieved.
Jan 27, 2026, 1:19 PM
8-K
Intellia Therapeutics Updates on Clinical Pipeline and Financial Outlook
NTLA
Product Launch
Guidance Update
New Projects/Investments
  • Intellia Therapeutics' Lombozi program for hereditary angioedema (HAE) has completed enrollment for its Phase 3 HAELO trial, with top-line data anticipated by mid-2026, a Biologics License Application (BLA) submission in H2 2026, and a commercial launch expected in H1 2027.
  • The Nexi program for transthyretin amyloidosis (TTR) is currently under a clinical hold by the FDA, which was triggered by a patient death due to septicemia from a perforated duodenal ulcer, not liver failure. Intellia is actively engaged with the FDA to resolve the hold.
  • The company reports a strong financial position, with capital to fund operations into mid-2027.
Jan 14, 2026, 5:00 PM
Transcript
Intellia Therapeutics Provides Clinical and Financial Updates at JPMorgan Healthcare Conference
NTLA
Product Launch
New Projects/Investments
Guidance Update
  • Intellia Therapeutics announced the completion of enrollment for its Lombozi (HAE) Phase 3 Halo trial, with top-line data expected by mid-2026, a Biologics License Application (BLA) submission in H2 2026, and a commercial launch targeted for H1 2027.
  • The company's Nexi (TTR amyloidosis) Phase 3 trials (Magnitude and Magnitude-2) are currently on clinical hold, with Intellia actively engaged with the FDA for resolution.
  • Intellia clarified that the patient death which led to the Nexi clinical hold was attributed to septicemia from a perforated duodenal ulcer, not liver failure.
  • Intellia maintains a strong capital position, providing funding for operations into mid-2027.
Jan 14, 2026, 5:00 PM
Transcript
Intellia Therapeutics Provides Update on Late-Stage Clinical Programs and Financial Outlook
NTLA
Product Launch
New Projects/Investments
Guidance Update
  • Intellia Therapeutics, a leader in CRISPR medicine, is advancing two late-stage clinical programs: Lombozi for hereditary angioedema (HAE) and Nexi for transthyretin amyloidosis (TTR).
  • For Lombozi, the Phase 3 Halo trial enrollment is complete, with top-line data anticipated by mid-2026, BLA submission in H2 2026, and a commercial launch targeted for H1 2027.
  • The Nexi Phase 3 programs for TTR amyloidosis are currently under clinical hold, with resolving this hold being a top priority for 2026. The hold was triggered by a patient who succumbed to septicemia due to a perforated duodenal ulcer, not liver failure.
  • The company maintains a strong capital position, providing funding for operations into mid-2027.
Jan 14, 2026, 5:00 PM
Transcript
Intellia Therapeutics provides update on nex-z clinical holds and lonvo-z development
NTLA
New Projects/Investments
Guidance Update
Product Launch
  • Intellia Therapeutics' nexiguran ziclumeran (nex-z) MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for transthyretin (ATTR) amyloidosis are on clinical hold following a Grade 4 liver transaminase elevation in a patient who subsequently passed away on November 5, 2025, due to septic shock secondary to a perforated duodenal ulcer.
  • The company is working to resolve the clinical holds and plans to provide an update after finalizing a path forward with regulators for nex-z.
  • Intellia expects to present topline Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) by mid-2026, with a Biologics License Application (BLA) submission planned for the second half of 2026 and a U.S. commercial launch in the first half of 2027.
  • Intellia anticipates its existing capital will fund operations into mid-2027.
Jan 9, 2026, 1:07 PM
8-K

Earnings Transcripts

Quarterly earnings call transcripts for Intellia Therapeutics.

Q4 2025

Feb 26, 2026

→

Q2 2025

Aug 7, 2025

→

Q1 2025

May 8, 2025

→
View All Transcripts
Fintool

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did John Leonard say about margins?What are Intellia Therapeutics's strategic priorities?How is Intellia Therapeutics positioned vs competitors?How did Intellia Therapeutics do last quarter?